A study to evaluate the risk of metabolic syndrome, cardiovascular risk, and renal impairment in HIV-infected patients initiating antiretroviral therapy (ART) in the GUESS cohort.

At a glance
Trial Overview
Trial Details
Interventions
Results
- Publications
Authors
Trial History
References

Trial Profile

A study to evaluate the risk of metabolic syndrome, cardiovascular risk, and renal impairment in HIV-infected patients initiating antiretroviral therapy (ART) in the GUESS cohort.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
Indications HIV infections
Focus Adverse reactions
Acronyms GUESS

Most Recent Events

01 Mar 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com